An open label, phase Ib, dose-escalation study evaluating the safety & tolerability of BI 836845 andabemaciclib in patients with locally advanced or
|Effective start/end date||1/1/17 → 3/31/26|
- BOEHRINGER-INGELHEIM PHARMACEUTICALS
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.